MetaCap

Allogene Therapeutics Inc. Company Profile

NASDAQ: ALLOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.6277-0.0392 (-5.88%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Allogene Therapeutics at a glance

Allogene Therapeutics Inc. (NASDAQ: ALLO) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in South San Francisco, CA. Allogene Therapeutics is led by Dr. Zachary J. Roberts M.D., Ph.D. and employs about 150 people. The company's shares have traded publicly since 2018.

At a market capitalization of $217.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001737287, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Allogene Therapeutics do?

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Business description based on the company's public filings.

Company information

Legal name
Allogene Therapeutics Inc.
Ticker
NASDAQ: ALLO
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Zachary J. Roberts M.D., Ph.D.
Employees
150
Headquarters
210 East Grand Avenue, South San Francisco, CA, United States
Phone
650 457 2700
IPO year
2018
Market cap
$217.48M
SEC CIK
0001737287
Latest annual report
10-K · Mar 12, 2026

Companies similar to Allogene Therapeutics

ALLO peer companies
CompanyPrice% ChgMarket capCompare
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs ALLO
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs ALLO
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs ALLO
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs ALLO
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs ALLO
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs ALLO
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs ALLO
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs ALLO

Related